SOURCE: HCi Viocare

HCi Viocare

HCi Viocare

April 12, 2016 12:28 ET

HCi Viocare's Innovative FLEXISENSE Technology Demonstrated at the John Hancock Sport & Fitness Expo in Boston

GLASGOW, SCOTLAND--(Marketwired - Apr 12, 2016) - UK-based bio-engineering company HCi Viocare Technologies, a wholly owned subsidiary of HCi Viocare (OTCQB: VICA) (the "Company"), is participating at the John Hancock Sport & Fitness Expo, which will open on April 15 at the Hynes Convention Center in Boston, Massachusetts, USA. HCi Viocare Technologies' participation aims to demonstrate its groundbreaking pressure and shear sensing technology FLEXISENSE in one of its most extreme implementations, the Smart Sports Insole.

The John Hancock Sports & Fitness Expo which kicks off the Boston Marathon weekend is one of the most significant events in the sports industry calendar, featuring the leading sport and athletic companies and attracting more than 100,000 attendees, including the world's top marathoners, elite athletes, fitness enthusiasts, thousands of serious runners, and the general public.

All visitors and participants at the exhibition can visit HCi Viocare's booth, and try the Company's interactive Smart Flexisense Insole.

The Sports Smart Insole is one of the most eagerly awaited applications of the FLEXISENSE technology, building on the momentum of the wearable devices sector. Incorporated into shoe construction or as a stand-alone insole, Flexisense sensors provide the user with on-demand information, contributing in performance enhancement, providing gait analysis and activity impact on the joints and knees as well as preventing injury and monitoring shoe wear.

HCi Viocare's business model for FLEXISENSE is based on licensing the technology, aiming to incorporate FLEXISENSE into different products. The Company is targeting highly innovative manufacturers within different industries that focus on gaining competitive advantages through incorporating new technologies into their products.

Dr. Christos Kapatos, HCi Viocare's co-founder and CTO stated: "The uniqueness of FLEXISENSE lies in its ability to measure pressure and shear in real time, and feed back performance information to the user wirelessly. Our goal is to incorporate the Flexisense technology into many different products, providing cost effective solutions which meet people's needs, improving their health, wellbeing and everyday experience."

About HCi Viocare Clinics

The company is a Glasgow-based subsidiary of HCi Viocare, which has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants. HCi Viocare is listed in the OTC Markets in the USA, and has its executive office in Athens, Greece and R&D centre in Glasgow, UK. Please visit: www.hciviocare.com Glasgow Clinic web site: www.hci-viocare.co.uk

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas of athletic shoes and the information and performance of the company's technology in such applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a "smart insole" with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

Contact Information